Metabolic Dysfunction-Associated Fatty Liver Disease Shows Distinct Pathogenic Pathways

Research presented by scientists at Menoufia University has highlighted the complex relationship between cumulative metabolic burden and the severity of hepatic fibrosis and steatosis in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). The study revealed that metabolic burden strongly predicts steatosis but not fibrosis, indicating distinct pathogenic pathways. Fibrosis, on the other hand, was found to be associated with age, diabetes, and biochemical markers, whereas steatosis reflects cumulative metabolic clustering, particularly obesity.

Key Takeaways:

• The study assessed 357 MAFLD patients classified by metabolic burden, with 16.4%, 21.9%, and 39.5% of patients across subtypes 1-3 showing increased steatosis.
• Advanced fibrosis was infrequent (5.3%) and showed no significant variation across metabolic burden subgroups (p = 0.907).
• Multivariate analysis identified age (OR = 1.16, p = 0.008) and diabetes (OR = 4.40, p = 0.033) as significant predictors of fibrosis, while metabolic burden was associated with steatosis.
• A free version of the journal article is available at https://doi.org/10.1186/s43066-025-00468-2.

Statistics:

• 357 MAFLD patients were classified by metabolic burden in the study.
• 16.4%, 21.9%, and 39.5% of patients across subtypes 1-3 showed increased steatosis.
• 5.3% of patients showed advanced fibrosis.
• Fibrosis was more common in patients with diabetes (OR = 4.40, p = 0.033).

Sources:

• Association of metabolic risk factors with the severity of hepatic fibrosis and steatosis in metabolic dysfunction-associated fatty liver disease patients. Egyptian Liver Journal, 2025, 15(1):1-7.
• Egyptian Liver Journal is published by SpringerOpen.
• DOI: https://doi.org/10.1186/s43066-025-00468-2.